The antibodies of programmed cell death receptor 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) have been applied as ICIs for the treatment of breast cancer. Here, PDCD1 is linked to breast carcinoma.